Kiniksa Pharmaceuticals, Ltd. (KNSA) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Hamilton, Bermuda. वर्तमान CEO हैं Sanj K. Patel.
KNSA के पास है IPO तिथि 2018-05-25, 315 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $3.41B.
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing innovative therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. The company's product portfolio includes ARCALYST, an approved treatment for recurrent pericarditis, along with several clinical-stage candidates including Mavrilimumab for giant cell arteritis, Vixarelimab for prurigo nodularis, and KPL-404 targeting immune-mediated disorders. Founded in 2015 and headquartered in Hamilton, Bermuda, Kiniksa is committed to addressing serious inflammatory and immunological conditions with limited existing treatment options.
